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Endothelial to mesenchymal transition is common
in atherosclerotic lesions and is associated with
plaque instability
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Endothelial to mesenchymal transition (EndMT) plays a major role during development, and
also contributes to several adult cardiovascular diseases. Importantly, mesenchymal cells
including ﬁbroblasts are prominent in atherosclerosis, with key functions including regulation
of: inﬂammation, matrix and collagen production, and plaque structural integrity. However,
little is known about the origins of atherosclerosis-associated ﬁbroblasts. Here we show using
endothelial-speciﬁc lineage-tracking that EndMT-derived ﬁbroblast-like cells are common in
atherosclerotic lesions, with EndMT-derived cells expressing a range of ﬁbroblast-speciﬁc
markers. In vitromodelling conﬁrms that EndMT is driven by TGF-b signalling, oxidative stress
and hypoxia; all hallmarks of atherosclerosis. ‘Transitioning’ cells are readily detected in
human plaques co-expressing endothelial and ﬁbroblast/mesenchymal proteins, indicative of
EndMT. The extent of EndMT correlates with an unstable plaque phenotype, which appears
driven by altered collagen-MMP production in EndMT-derived cells. We conclude that EndMT
contributes to atherosclerotic patho-biology and is associated with complex plaques that may
be related to clinical events.
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E
pithelial to mesenchymal transition (EMT) and endothelial
to mesenchymal transition (EndMT) are fundamental
processes during development, including the cardiovascular
system. Notably, only days after conception typically at
the blastocyst stage, the trophoblast sends forward columns
of epithelial cells that penetrate the maternal uterine wall,
undergo EMT, and establish an early placental blood supply
by invading the maternal decidual interstitium and vessels1. Thus,
interestingly, there is a very early precedent for the involvement
of EMT in vascular biology. Soon thereafter, EMT plays a
pivotal role in germ layer speciﬁcation, when cells from the
primitive epiblast layer undergo EMT to give rise to mesoderm
and endoderm. This central role for EMT continues throughout
development, and genetic knockout mice harbouring mutations
involving transforming growth factor-b (Tgf-b) and other
central pathways governing EMT are often embryonic lethal
(see reviews2–4). With speciﬁc respect to cardiac development,
endocardial cells in the region of the forming atrioventricular
canal undergo EndMT (a type of EMT involving endothelial cells)
to give rise to mesenchymal cells that form the endocardial
cushion tissue (precursor of the semilunar valves)5,6, while
epicardial cells also undergo EMT to give rise to epicardium-
derived cells that form smooth muscle cells, interstitial cardiac
stromal cells and potentially a sub-population of endothelial cells
(see reviews2,4).
In the adult, it has been increasingly appreciated that EMT and
EndMT play a major role in chronic ﬁbrosing-type injuries and
diseases (see reviews2,3). In the cardiovascular system, this includes
contributions to the pathologies of pulmonary hypertension7,8,
transplant arteriopathy9,10, vascular malformations11, myocardial
infarction12, vascular calciﬁcation,13 ﬁbrodysplasia ossiﬁcans
progressiva14 and a somewhat more controversial role4 in
cardiac ﬁbrosis15,16. In addition, we have shown that EndMT
makes a major contribution to the vascular remodelling and
neointimal formation that arises following vein graft
transplantation into the arterial circulation17. This process is
dependent on early activation of the Smad2/3-Snai2 signalling
pathway, with antagonism of Tgf-b signalling resulting in
decreased EndMT and reduced neointimal formation17. Recently,
Chen et al.18 extended our understanding of EndMT and
demonstrated that it promotes atherosclerosis progression,
however, the principal mesenchymal cell type that is derived
from EndMT in atherosclerosis was not deﬁned by their study,
nor was the extent of the contribution of EndMT-derived
mesenchymal cells addressed.
Importantly, mesenchymal cells including ﬁbroblasts are
prominent in atherosclerosis, with ﬁbroblast-speciﬁc proteins
being highly expressed in advanced atherosclerotic lesions19,20.
Key functions for ﬁbroblasts in atherosclerosis include regulation
of: inﬂammation19,21, extra-cellular matrix and collagen
production19, and plaque structural integrity19,22. However,
unlike other cell types in atherosclerotic plaques, essentially
nothing is known about the origins of atherosclerosis-associated
ﬁbroblasts. Therefore, based on the fact that atherosclerosis is an
archetypal example of a TGF-b-mediated ﬁbrosing vascular disease
of adults23,24, we elected to investigate whether EndMT contributes
to atherosclerotic plaque formation. We identiﬁed that
EndMT-derived ﬁbroblast-like cells are common in intimal
atherosclerotic plaques. These ﬁndings were corroborated using
both Cre-lox endothelial lineage tracking in mice, and in human
plaques by detecting cells co-expressing endothelial and ﬁbroblast/
mesenchymal proteins, indicative of EndMT. The number of
transitioning cells was associated with an unstable and ruptured
human plaque phenotype, which appears mechanistically driven by
altered collagen-matrix metalloproteinase (MMP) production in
EndMT-derived ﬁbroblast-like cells. We conclude that EndMT
contributes to atherosclerotic patho-biology and is associated with
complex plaques that may be prone to rupture and cause clinical
events.
Results
Endothelial lineage-tracking system in atherosclerotic mice.
For endothelial lineage-tracking in the setting of EndMT, prior
studies have typically used constitutively active systems, such as
Tie1Cre or Tie2Cre mice14,15. While these models have robust Cre
recombination in endothelial-derived cells, they suffer from the
limitation that a majority of circulating leukocytes exhibit Cre
recombination. In preliminary experiments we conﬁrmed that
450% of circulating leukocytes in Tie2Cre;R26RstopYfp mice
express Yfp (Supplementary Fig. 1a). Because atherosclerotic
plaques involve a rich contribution from monocytes and other
leukocytes, constitutively active endothelial lineage-tracking
systems were inappropriate for studying EndMT in atherosclerosis.
We therefore created a tamoxifen-inducible endothelial line-
age-tracking system; the end.SclCreERT;R26RstopYfp;ApoE /
mouse line (Fig. 1). The end.SclCreERT line has been extensively
validated and used to study EndMT12,16,17,25. In atherosclerosis-
prone end.SclCreERT;R26RstopYfp;ApoE / mice, endothelial-
speciﬁc Cre expression is induced by tamoxifen administration to
irrevocably activate the yellow ﬂuorescence protein (Yfp) gene,
resulting in continuous Yfp expression regardless of any change
in cell phenotype26,27. As tamoxifen was administered beginning
at 4 weeks of age (after the embryonic ‘hemogenic endothelial’
period), Cre recombination in bone marrow cells and circulating
leukocytes was avoided. To enhance plaque development, mice
received a high-fat diet (HFD) from 6 weeks of age. Unlike
constitutively active Tie2Cre;R26RstopYfp mice, by ﬂuorescence-
activated cell sorting (FACS) analysis of tamoxifen-induced
end.SclCreERT;R26RstopYfp and end.SclCreERT;R26RstopYfp;
ApoE / mice we were unable to detect circulating
CD45þYfpþ cells (Supplementary Fig. 1b,c).
We ﬁrst conﬁrmed the sensitivity and speciﬁcity of this model
for endothelial lineage-derived cell tracking. Immunoﬂuorescence
staining of Yfp and CD31 in the aortas of tamoxifen-induced
end.SclCreERT;R26RstopYfp;ApoE / mice after 8, 18 or 30
weeks of HFD revealed the expected pattern of Yfp expression by
CD31þ endothelial cells in the presence of atherosclerotic
lesions (Supplementary Fig. 2a–d). Consistent with prior EndMT
studies using end.SclCreERT;R26RstopYfp mice17, FACS revealed
that a mean of 30.7±12.5% of CD31þ endothelial cells in
end.SclCreERT;R26RstopYfp;ApoE / mice co-expressed Yfp
after 8 weeks of HFD (n¼ 5 mice) (Supplementary Fig. 2e).
This FACS-derived data was used for all subsequent
determinations of the proportion of cells undergoing EndMT.
We conﬁrmed these FACS data by immunoﬂuorescence staining
and blinded cell counting, with 53.2±12.2% of CD31þ
endothelial cells in end.SclCreERT;R26RstopYfp;ApoE / mice
co-expressing Yfp after 8 weeks of HFD (n¼ 5 mice). Consistent
with the ﬁnding that CD45þ cells do not express Yfp in our
model (Supplementary Fig. 1c), by immunoﬂuorescence staining
of aortic sections we were unable to detect any Yfpþ cells that co-
expressed CD45 or CD68 (Supplementary Fig. 2f,g).
EndMT gives rise to ﬁbroblast-like cells in atherosclerosis. As
a fundamental EndMT mediator, we sought to conﬁrm
Tgf-b expression in atherosclerotic plaques from end.SclCreERT;
R26RstopYfp;ApoE / mice. Consistent with its known role in
atherosclerosis23,24, Tgf-b was identiﬁed within the intima and in
developed plaques at all time-points and was expressed by both
CD68þ macrophages and a-smooth muscle actin (aSma)þ cells
(Supplementary Fig. 3a,b).
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To investigate whether EndMT may arise during atherosclerosis,
thoracic aortic plaques from tamoxifen-induced end.SclCreERT;
R26RstopYfp;ApoE / mice were evaluated for cellular
co-expression of Yfp and ﬁbroblast marker proteins. We initially
evaluated co-expression of the ﬁbroblast-speciﬁc marker ﬁbroblast
activation protein (Fap), which is expressed by inﬂammatory- and
cancer-associated stromal cells and ﬁbroblasts28, and which is also
expressed in atherosclerotic plaques19. Importantly, recent studies
of genetically marked Fapþ cells conﬁrmed a lack of Fap
expression by endothelial cells29. Immunoﬂuorescence confocal
microscopy of aortic plaques revealed a signiﬁcant number of
endothelial lineage-derived Yfpþ cells co-expressing Fap
(Fig. 2a–c), indicative of EndMT. Image reconstruction and
z-stack analysis resolved FapþYfpþ co-positive cells at the
single cell level, eliminating experimental artefact due to cellular
overlay or superimposition (Supplementary Movie 1). We found
that Fapþ ﬁbroblasts constitutedB25% of all intimal plaque cells
in mature plaques after 18 or 30 weeks of HFD (Fig. 2d). After
counting crude numbers of FapþYfpþ cells (Fig. 2e) and then
correction for efﬁciency of Yfp expression among CD31þ cells in
our murine model, we established that 32.5±8.5% of intimal
plaque Fapþ cells were endothelial-derived after 8 weeks of HFD,
while 45.5±23.3% of intimal Fapþ cells were endothelial-derived
in mice with advanced atherosclerotic lesions after 30 weeks HFD
(Fig. 2f). Overall, endothelial-derived Fapþ cells represented 3–9%
of all intimal plaque cells (Fig. 2g). Differences between
these groups in Fig. 2d–g were not signiﬁcant, indicating a
relatively constant proportional contribution of EndMT-derived
cells to the intimal Fapþ ﬁbroblast population. Four colour
immunoﬂuorescence confocal microscopy showed that particularly
in the deeper aspect of intimal plaques (adjacent to the
plaque ‘core’), YfpþFapþ endothelial lineage-derived cells
could be identiﬁed that did not express the endothelial protein
Ve-Cadherin, suggestive of endothelial transition towards a
more mature ﬁbroblast-like phenotype (Fig. 2h). Quantitation
demonstrated that among the entire intimal Fapþ ﬁbroblast
population, 9.8±4.1% of cells were Yfpþ endothelial-derived cells
that had lost Ve-Cadherin protein expression, while 9.3±1.9%
were YfpþVe-Cadherinþ double positive cells, the latter likely
indicative of cells transitioning from an endothelial to ﬁbroblast-
like phenotype (Fig. 2i). Conversely, among the entire Yfpþ
endothelial-derived intimal cell population, 11.7±4.8% of cells
were Fapþ but had lost Ve-Cadherin expression, while 11.1±2.2%
were FapþVe-Cadherinþ double positive cells (Fig. 2j).
As ﬁbroblasts were very rarely seen in the media (Fig. 2;
Supplementary Fig. 4), we next investigated if YfpþFapþ
endothelial lineage-derived ﬁbroblast-like cells also exist in the
adventitia during atherosclerosis (Supplementary Fig. 4a–c). In
the adventitia, Fapþ ﬁbroblasts constituted B30–35% of cells at
all time-points (Supplementary Fig. 4d). After counting crude
numbers of YfpþFapþ cells (Supplementary Fig. 4e), correction
for efﬁciency of Yfp expression revealed that 7–16% of Fapþ
adventitial ﬁbroblast-like cells were derived from endothelial
lineage cells (Supplementary Fig. 4f), with endothelial
lineage-derived Fapþ cells representing 2–5% of all adventitial
cells (Supplementary Fig. 4g).
We further conﬁrmed the contribution of endothelial lineage-
derived cells to Fapþ ﬁbroblasts by performing FACS for Fap
expression among Yfpþ cells. Interestingly we found that in 24
week old non-atherosclerotic end.SclCreERT;R26RstopYfp mice
receiving chow diet, 21.5±0.2% of Yfpþ cells expressed Fap,
while in age-matched tamoxifen-induced end.SclCreERT;
R26RstopYfp;ApoE / mice that received 18 weeks of HFD,
36.2±3.6% of Yfpþ cells expressed Fap (Fig. 2k). In distinction
from our results presented so far (Fig. 2a–g; Supplementary
Fig. 4) where we evaluated the proportion of Fapþ cells that were
endothelial-derived, these data reﬂect the proportion of all
endothelial and endothelial-derived cells that are potentially
undergoing or have undergone EndMT and are expressing Fap.
These data suggested that a signiﬁcant number of intimal and
adventitial ﬁbroblast-like cells in atherosclerotic lesions are
derived via EndMT. These ﬁndings were conﬁrmed using another
marker, ﬁbroblast-speciﬁc protein-1 (Fsp-1 or S100a4). While
recent data has emerged suggesting Fsp-1 is not entirely speciﬁc
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Figure 1 | Breeding and generation of end.SclCreERT;R26RstopYfp;ApoE / mice. This ﬁgure was created using Servier medical art.
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for ﬁbroblasts30, by immunoﬂuorescence confocal microscopy,
compared with Fap staining, we identiﬁed a similar number of
Fsp-1þ cells that co-expressed Yfp (Supplementary Fig. 5;
Supplementary Movie 2), supporting the occurrence of EndMT
in atherosclerosis. As a third marker of ﬁbroblasts and
mesenchymal cells, immunoﬂuorescence confocal microscopy
performed using an anti-Vimentin antibody again conﬁrmed
a signiﬁcant number of endothelial lineage-derived Yfpþ cells
co-expressing this additional marker in atherosclerotic plaques
(Supplementary Fig. 6).
We next sought to ascertain if endothelial lineage-derived cells
might also give rise to myoﬁbroblasts or vascular smooth muscle
cells (VSMCs). While detectable, Yfpþ cells that also expressed
the proteins aSma, Sm22a or smooth muscle myosin heavy chain
(Smmhc) were less commonly observed than ﬁbroblasts, with the
proportional contribution of endothelial lineage-derived cells to
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tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE / mice after (a) 8, (b) 18, (c) 30 weeks of HFD revealed Yfpþ cells co-expressing ﬁbroblast-speciﬁc
marker Fap within intimal plaques. L¼ lumen; scale bars, 100mm. Insets at higher magniﬁcation as indicated. Arrows indicate co-positive cells. (d) Cell
quantitation in intimal plaques revealed that after 8, 18 and 30 weeks of HFD, 10.2±2.1%, 25.7±9.0% and 25.6±6.3% (respectively) of cells expressed Fap,
indicative of a ﬁbroblast phenotype. (e) Quantitation (not accounting for the proportion of endothelial cells expressing Yfp) identiﬁed that at the same time-
points, 10.0±2.6%, 6.4±3.9% and 14.0±7.2% (respectively) of intimal Fapþ cells co-expressed Yfp. (f) After accounting for the efﬁciency of our
endothelial lineage tracking system (% of endothelial cells expressing Yfp), at the same time-points, we determined that 32.5±8.5%, 20.7±12.6% and
45.5±23.3% of intimal Fapþ cells were endothelial lineage-derived. (g) Again taking into account the efﬁciency of our endothelial lineage tracking system, at
the same time-points, respectively, we determined that 3.1±1.0%, 3.0±1.4% and 8.8±4.7% of all intimal cells were endothelial lineage-derived Fapþ cells.
For Fig. 1e–h staining was performed with at least four images evaluated from each of at least three spatially separated thoracic aortic sections per mouse
(n¼ 5 mice for 8 and 18 weeks; n¼4 mice for 30 weeks). Data were averaged per animal then used for statistical analyses (one-way ANOVA). NS, not
signiﬁcant. (h) Four colour immunoﬂuorescence confocal microscopy of thoracic aortic sections from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE /
mice after 18 weeks HFD demonstrating YfpþFapþVe-Cadherinþ (arrow heads) and YfpþFapþVe-Cadherin cells (arrows). L¼ lumen; scale bars, 100mm.
Quantitation of Yfpþ , Fapþ and Ve-Cadherinþ (VeCad) cells in intimal plaques as shown in h was performed (n¼ 5 mice) to assess (i) the relative
co-expression of Yfp and Ve-Cadherin among all Fapþ cells (j) the relative co-expression of Fap and Ve-Cadherin among all Yfpþ cells. (k) Fap expression
was assessed among Yfpþ cells by FACS revealing that in control non-atherosclerotic end.SclCreERT;R26RstopYfp mice receiving chow diet, 21.5±0.2% of
Yfpþ cells expressed Fap, while in tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE / mice after 18 weeks of HFD, 36.2±3.6% of Yfpþ cells expressed
Fap. All mice studied in panel k were of the same overall age (24 weeks). *Po0.05, n¼ 3 per group.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11853
4 NATURE COMMUNICATIONS | 7:11853 | DOI: 10.1038/ncomms11853 | www.nature.com/naturecommunications
aSmaþ and Sm22aþ populations beingB10-fold lower than to
ﬁbroblast-like cells (Supplementary Fig. 7).
Oxidative stress promotes EndMT. We next investigated the
molecular mechanisms underlying endothelial lineage
speciﬁcation of ﬁbroblast-like cells during EndMT. While its role
in EndMT is essentially unknown, prior studies have documented
that oxidative stress is an important factor during the
related process of EMT31,32, and we speculated that this may be of
relevance during EndMT in atherosclerotic plaques. We ﬁrst
identiﬁed that intimal plaques from end.SclCreERT;
R26RstopYfp;ApoE / mice exhibit marked oxidative stress,
which was signiﬁcantly greater in more advanced lesions (Fig. 3a).
While oxidative stress was also observed in the adventitia, in
vessels from mice with advanced atherosclerosis there was
signiﬁcantly less oxidative stress observed in the adventitia than
in intimal plaques (Fig. 3a). We also performed TUNEL staining
to assess for apoptosis, and found substantial intimal Yfpþ cell
apoptosis in early plaques, that was signiﬁcantly increased in
more advanced intimal plaques (Fig. 3b). Control vessels from
non-atherosclerotic mice did not show appreciable oxidative
stress or cell apoptosis (Supplementary Fig. 8). We proceeded to
evaluate the independent and combined effects of TGF-b
(a known EndMT mediator) and/or hydrogen peroxide (H2O2)
(an inducer of oxidative stress) on human umbilical vein
endothelial cells (HUVECs). Exposure to TGF-b or H2O2
caused a dose-responsive change in morphology, with HUVECs
progressively losing their cobblestone appearance and adopting a
dispersed, spindle-shaped morphology, with these changes being
further enhanced when TGF-b and H2O2 were applied together
(Fig. 3c). When TGF-b alone was applied, at the dose used to
induce EndMT there was no change in cell count, proliferation,
apoptosis or death. However, consistent with the induction of
cellular stress, H2O2 caused a dose-responsive decrease in cell
number, with a reduction in cell proliferation and an increase in
cell apoptosis and death (Supplementary Fig. 9; Supplementary
Table 1). Global transcriptome analysis identiﬁed that
the application of TGF-b alone to HUVECs caused the
upregulation of a total 1,363 genes/transcription factors and
downregulated 1,295, while the application of TGF-b plus 200 mM
H2O2 upregulated 3,366 genes/transcription factors and
downregulated 2,934 (signiﬁcance analysis of microarrays-based
differential expression33,34; all Po0.05 after correction for
multiple comparisons). Among these, a broad range of
EndMT/EMT-related and mesenchymal genes were upregulated
by TGF-b alone (Fig. 3d; Supplementary Table 2). However, the
combined application of TGF-bþH2O2 produced a greater,
additive induction of EndMT with concurrent downregulation of
endothelial gene expression (Fig. 3d; Supplementary Table 2).
These ﬁndings were veriﬁed by quantitative real-time PCR
(qRT-PCR) and western blot, with H2O2 activating EndMT in
HUVECs in an incremental and dose-responsive manner that
was signiﬁcantly more effective than TGF-b alone (Fig. 3e–h;
Supplementary Tables 3 and 4; Supplementary Fig. 10a,b).
Consistent with the transition to a mesenchymal phenotype,
HUVECs treated with TGF-bþH2O2 demonstrated enhanced
migration and invasion as compared to unstimulated control
HUVECs (Fig. 3i,j).
We then further investigated expression and activation of
signalling pathways regulating EndMT in the vasculature17.
Supporting our hypothesis that oxidative stress promotes
EndMT in atherosclerotic plaques, TGF-bþH2O2 caused an
additive and signiﬁcant increase in the RNA expression level of
TGF-b signalling pathway member and EndMT mediator SNAI2
(Supplementary Fig. 10c). On the other hand, SNAI1 was only
increased by TGF-b, while SMAD2 levels were not affected
by either TGF-b or H2O2. Expression of SMAD3 was increased
by H2O2 but unexpectedly decreased by TGF-b (Supplementary
Fig. 10d–f). Western blot analysis conﬁrmed that H2O2 had
an independent effect on SMAD3 protein levels in HUVECs,
while there was no change in SMAD3 protein levels in
response to TGF-b. Moreover, both H2O2 and TGF-b led to an
increase in SMAD3 phosphorylation (Supplementary Fig. 10g;
Supplementary Table 4).
Analysis of pathways that were enriched in upregulated genes
indicated that at the doses used for EndMT induction, TGF-b
alone did not activate any speciﬁc pathways in HUVECs
(Supplementary Fig. 11a). However, TGF-bþH2O2 caused
upregulation of a number of pathways (Supplementary
Fig. 11b). Consistent with our ﬁnding that oxidative
stress mediates EndMT, many of the pathways upregulated by
TGF-bþH2O2 were related to ﬁbrosis (for example, hepatic
ﬁbrosis / hepatic stellate cell activation), inﬂammation (for
example, leukocyte extravasation signalling) or oxidative stress
itself (for example, NRF2-mediated oxidative stress response).
Interestingly, we found that several interferon-related pathways
were upregulated, while the most signiﬁcantly upregulated
pathway was the protein ubiquitination pathway
(Supplementary Fig. 11b). While we are unaware that ubiquitina-
tion or interferon signalling have been investigated during
EndMT, both have been implicated in EMT35–37.
Because EndMT in the context of atherosclerosis requires that
arterial (rather than venous) endothelial cells transition to a
mesenchymal state, we evaluated the ability of human coronary
artery endothelial cells (HCAECs) to undergo EndMT. Mirroring
our results with HUVECs, H2O2 with or without TGF-b
demonstrated an incremental effect on EndMT induction in
HCAECs (Supplementary Fig. 12).
Severe hypoxia promotes EndMT. As another mediator of
oxidative stress, hypoxia is a fundamental aspect of
atherosclerotic biology. While it is known to promote EMT38, the
effects of hypoxia on EndMT have not been extensively assessed.
We initially veriﬁed that hypoxia was present in atherosclerotic
plaques of HFD-fed end.SclCreERT;R26RstopYfp;ApoE / mice,
ﬁnding that with progressive atherosclerosis there is a marked
increase in the percentage of hypoxic cells in intimal plaques
(Fig. 4a). Furthermore we found that in mature plaques there are
more hypoxic cells in intimal plaques than in the adventitia
(Fig. 4a). We next proceeded to evaluate the effect of hypoxia on
EndMT. Immunostaining of HCAECs exposed to hypoxia,
TGF-b, or both hypoxia and TGF-b, indicated that EndMT
arose under each of these conditions (Fig. 4b). Evaluation of RNA
expression demonstrated that hypoxia caused a 3–6-fold increase
in the expression of a range of ﬁbroblast and mesenchymal
markers (Fig. 4c–f). Interestingly, the effect of hypoxia on the
expression of certain endothelial genes was borderline (Fig. 4g–j),
and in a single case went in an unexpected direction (Fig. 4h),
which we expect may be due to the fact that modest hypoxia is
known to promote endothelial gene expression39. Therefore
severe hypoxia, as was applied in this case and as is relevant to
atherosclerosis, appears to promote mesenchymal gene
expression while having a mixed effect on endothelial genes.
Nevertheless, consistent with EndMT, both SNAI2 and SNAI1
were upregulated by hypoxia in HCAECs (Fig. 4k,l). Western blot
analyses further veriﬁed these observations (Fig. 4m,n).
EndMT occurs in human atherosclerotic plaques. In vivo
lineage tracking of EndMT is not currently possible in
humans. However, as we observed in vitro and in our
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Figure 3 | Oxidative stress promotes EndMTand has additive effects to TGF-b. (a) Representative dihydroethidium (DHE) microscopy images of thoracic
aortic sections from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE / mice after 8 versus 18 weeks HFD demonstrating in situ superoxide production.
Analysis by one-way ANOVA; overall Po0.0001. (b) TUNEL assay on atherosclerotic lesions from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE /
mice after 8 versus 18 weeks HFD demonstrating apoptotic Yfpþ cells. For a and b: L¼ lumen; scale bars, 100mm. Insets at higher magniﬁcation as indicated.
Arrows indicate co-positive cells. Staining performed on at least three spatially separated thoracic aortic sections per mouse (n¼ 5 mice per group). Control
experiments from non-atherosclerotic mice shown in Supplementary Fig. 8. (c) Phase contrast microscopy of HUVECs grown in basal media (ctrl) or following
exposure to TGF-b and/or H2O2 for 5 days. Scale bars, 100mm. (d) Heatmap showing expression of endothelial genes (top), non-endothelial genes also
downregulated in EndMT/EMT, genes known to be upregulated in EndMT/EMTand mesenchymal genes (bottom) for HUVECs exposed to control conditions
(basal media—unstimulated), TGF-b or TGF-b plus 200mM H2O2. Because there are no gene sets for ‘EndMT’ or ‘ﬁbroblast’ in databases like GO, KEGG,
Reactome or MSigDB, this gene list was compiled by extensive literature search (Supplementary Table 2). (e) FAP protein expression by western blot with
quantiﬁcation in HUVECs exposed to control (ctrl) conditions (unstimulated) or TGF-b, with and without H2O2 at 100 or 200mM. FAP ladder (L) represents
100 kDa (upper) and 75kDa (lower intense band). FAP expected molecular weight/size is 90kDa. GAPDH ladder represents 37 kDa. GAPDH expected
molecular weight/size is 37 kDa. (f) FAP RNA levels assessed by qRT-PCR under identical conditions. (g) CD31 protein by western blot with quantiﬁcation.
CD31 ladder (L) represents 150 kDa (upper) and 100 kDa (lower intense band). CD31 expected molecular weight/size is 130 kDa. GAPDH ladder represents
37 kDa. GAPDH expected molecular weight/size is 37 kDa. (h) CD31 RNA levels assessed by qRT-PCR is presented for HUVECs under identical conditions.
Data in e–h analysed by two-way ANOVA with complete results in Supplementary Table 3. (i) Cell migration for unstimulated HUVECs versus after treatment
with TGF-b only or TGF-bþ 200mMH2O2 for 5 days. Analysis by one-way ANOVA; overall P¼0.015. (j) Cell invasion for unstimulated HUVECs versus after
treatment with TGF-b only or TGF-bþ 200mM H2O2 for 5 days. Analysis by one-way ANOVA; overall Po0.0001. n¼ 6–9 for qRT-PCR and 3–6 for western
blots. Migration and invasion determined from three independent experiments with each experiment having n¼ 3. NS, not signiﬁcant, *Po0.05, **Po0.01,
***Po0.001, ****Po0.0001.
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end.SclCreERT;R26RstopYfp;ApoE / model, cells undergoing
EndMT can be identiﬁed at various stages of transition, including
cells that simultaneously express endothelial and mesenchymal
markers (Fig. 2h–j). Therefore, to determine if EndMT is
operative in human atherosclerosis we evaluated and compared
plaques classiﬁed as type V (ﬁbrocalciﬁc lesions including
ﬁbroatheroma) versus type VI (complicated lesions with
vulnerable/unstable features)40 from human aortic post-mortem
samples for cells that co-express endothelial and mesenchymal
proteins. Using various combinations of markers, we identiﬁed
cells that expressed both endothelial and ﬁbroblast proteins,
indicative of cells undergoing EndMT. Quantitation of cells
expressing combinations of FAP/vWF, FSP-1/vWF, FAP/CD31
or FSP-1/CD31 revealed that in the order of 4–10% of intimal
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cells in type V lesions co-expressed endothelial and ﬁbroblast
proteins, compared with 10–18% of intimal cells in type VI
lesions (Fig. 5a–d). Importantly, differences between type V and
VI plaques were signiﬁcant for each of the endothelial-ﬁbroblast
marker combinations tested, indicating that a greater proportion
of cells are actively undergoing EndMT in complex and
unstable human atherosclerotic plaques (Fig. 5a–d). We
further identiﬁed that an increased proportion of FAPþ vWFþ
co-positive cells were present in ruptured versus non-ruptured
plaques (Fig. 5e), and supporting this observation, found an
inverse relationship between plaque ﬁbrous cap thickness and %
co-positive FAPþvWFþ cells within the plaque (Fig. 5f).
The inverse relationship between plaque ﬁbrous cap thickness
and % co-positive FAPþvWFþ cells persisted when the
analysis was limited to plaques with cap thickness of o100 mm
(Supplementary Fig. 13). This observation indicates a direct
relationship between the proportion of cells in human plaques
undergoing EndMT and a rupture-prone plaque phenotype with
thin ﬁbrous cap41.
We also performed co-staining of AHA type V plaques
(which are typically less inﬂammatory and with more
VSMCs than type VI lesions)22 with endothelial and
VSMC markers. Similar to our murine data, while B10-fold
less common than cells co-expressing endothelial and
ﬁbroblast markers, we identiﬁed that cells co-expressing
endothelial and VSMC markers constituted B1% of all intimal
plaque cells in AHA type V human plaques (Supplementary
Fig. 14).
EndMT is associated with altered collagen-MMP production.
We sought a mechanistic explanation for our observation that an
increased proportion of cells appeared to be undergoing EndMT
in complex and unstable human atherosclerotic plaques
and undertook to compare the molecular characteristics of
EndMT-derived cells with established human ﬁbroblast lines
(Supplementary Fig. 15). For this, global transcriptome analysis
was used to compare primary human ﬁbroblasts with HUVECs,
HUVECs treated with TGF-b only and HUVECs that were
induced to undergo EndMT by TGF-bþH2O2 according to our
in vitro model. Hierarchical clustering demonstrated that while
unstimulated and TGF-b-only treated HUVECs cluster together
and are intermixed on the resulting dendrogram, HUVECs
treated with TGF-bþH2O2 cluster separately (Fig. 6a).
However, human ﬁbroblasts clustered separately again from
all endothelial-derived cells (unstimulated, TGF-b-only and
TGF-bþH2O2-treated HUVECs) (Fig. 6a). This suggests
that cells that undergo EndMT acquire a gene expression pattern
that is different from an endothelial cell or ﬁbroblast, which we
henceforth refer to as EndMT-derived ﬁbroblast-like cells.
To understand and visualize this difference in lower dimensions,
we performed principal component analysis across all cell types
using the same terms as Fig. 3d (genes and transcription factors
associated with EndMT/EMT). Visualization of the ﬁrst three
principal components demonstrated that while HUVECs under
unstimulated and TGF-b-treated conditions are quite similar,
EndMT-derived ﬁbroblast-like cells (TGF-bþH2O2-treated
HUVECs) clustered between human ﬁbroblasts and unstimulated
HUVECs (Fig. 6b). These data indicate that the molecular
gene expression pattern of EndMT-derived ﬁbroblast-like cells
differs markedly from unstimulated endothelial cells, and that it is
intermediary with classical ﬁbroblasts.
We next compared mesenchymal and ﬁbroblast gene
expression levels between human ﬁbroblasts and EndMT-derived
ﬁbroblast-like cells (TGF-bþH2O2 treated HUVECs).
Supportive of a ﬁbroblast-like state of EndMT-derived cells,
while human ﬁbroblasts expressed higher levels of 13 of
19 mesenchymal/ﬁbroblast genes, the expression levels of 5
of 19 mesenchymal/ﬁbroblast genes were equivalent between
these cell populations, and a single gene (MYH9) was more highly
expressed in EndMT-derived ﬁbroblast-like cells (Fig. 6c).
To understand the mechanisms whereby EndMT-derived
ﬁbroblast-like cells are associated with a complex and unstable
plaque phenotype, we compared gene ontology (GO) extracellular
matrix terms between human ﬁbroblasts and EndMT-derived
ﬁbroblast-like cells, revealing signiﬁcant differences in
extracellular matrix gene expression patterns between these
populations (Fig. 6d). Compared with EndMT-derived
ﬁbroblast-like cells, human ﬁbroblasts expressed higher levels of
collagens (collagen 1A1, 1A2, 3A1, 5A2, 6A1, 6A2, 7A1, 8A2,
10A1, 11A1, 12A1, 16A1, 22A1), but lower levels of every MMP
except MMP3. In contrast, we found the opposite pattern in
EndMT-derived ﬁbroblast-like cells, with signiﬁcantly greater
expression of numerous MMPs (MMP 1, 2, 7, 10, 11, 14, 15) but
fewer collagens (collagen 4A1, 4A2, 4A5, 13A1, 17A1, 27A1), as
compared with human ﬁbroblasts (Fig. 6d). These ﬁndings were
conﬁrmed at the protein level, with an 8.2-fold increase in MMP
activity seen in conditioned media obtained from EndMT-derived
ﬁbroblast-like cells compared with human ﬁbroblasts (Fig. 6e).
Interestingly, there was 3-fold less MMP activity in the cell lysates
of EndMT-derived ﬁbroblast-like cells compared with human
ﬁbroblasts, suggesting that in addition to increased MMP gene
transcription, the global increase in MMP activity seen in the
conditioned media of EndMT-derived ﬁbroblast-like cells is likely
to also be due to increased MMP release (Fig. 6e). These ﬁndings
were further conﬁrmed by examining protein levels of speciﬁc
MMPs, with conditioned media from EndMT-derived
ﬁbroblast-like cells showing signiﬁcantly higher levels of MMPs
1, 9 and 10 as compared with human ﬁbroblasts (Fig. 6f). Given
that collagen is a hallmark of atherosclerotic plaque stability42,43,
while MMPs are destabilizing44,45, this provides a molecular
mechanism for our human observations, indicating that
Figure 4 | Hypoxia increases EndMTand is additive to the effect of TGF-b. (a) Representative pimonidazole staining demonstrating the extent of hypoxia
in aortic sections from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE / mice fed 8 versus 18 weeks HFD. Staining in red is indicative of hypoxia with
pO2o10mmHg. Speciﬁc staining was performed using pimonidazole (seen in red) and DAPI (blue). L¼ lumen; scale bars, 100mm. Staining was performed
on at least three spatially separated thoracic aortic sections per mouse (n¼ 5 mice per group). Analysis by one-way ANOVA; overall Po0.0001.
(b) Immunostaining of HCAECs exposed to hypoxia and/or TGF-b for 5 days in vitro. Scale bars, 100mm. (c–f) Relative RNA expression of mesenchymal genes
FAP, SM22a, Calponin and Versican (respectively) in HCAECs was increased by hypoxia as assessed by qRT-PCR. (g–j) Relative RNA expression of endothelial
genes CD31, Ve-Cadherin, eNOS and KDR assessed by qRT-PCR showed mixed effects in response to hypoxia. (k–l) Relative RNA expression of SNAI2 and
SNAI1 in HCAECs was increased by hypoxia. (m) SM22a protein expression, assessed by western blot in HCAECs, was increased by hypoxia as indicated.
SM22a ladder (L) represents 25 kDa (upper), 20kDa (middle) and 15 kDa (lower). SM22a expected molecular weight/size is 23 kDa. GAPDH ladder
represents 37 kDa. GAPDH expected molecular weight/size is 37 kDa. (n) CD31 protein expression, assessed by western blot in HCAECs. CD31 ladder (L)
represents 150 kDa. CD31 expected molecular weight/size is 130 kDa. GAPDH ladder represents 37 kDa. GAPDH expected molecular weight/size is 37 kDa.
As our intent was to evaluate the speciﬁc effect of hypoxia, and not interactions with TGF-b (which is provided as a reference), t testing was performed in this
case. n¼ 3 in all experiments. All experiments replicated 43 times. NS, not signiﬁcant, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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by altering the collagen-MMP balance EndMT-derived ﬁbroblast-
like cells may destabilize atherosclerotic lesions and enhance
clinical disease progression towards a collagen-poor, rupture-
prone plaque phenotype with thin ﬁbrous cap.
Discussion
In summary, we identiﬁed that EndMT-derived ﬁbroblast-like
cells make a signiﬁcant contribution to atherosclerotic plaques,
and that the molecular signature of these cells indicates an
important role in plaque destabilization. These ﬁndings are
consistent with numerous studies that have demonstrated a role
for EndMT or EMT in other chronic adult ﬁbrosing condi-
tions2,3,7–11,13–15,17. While other cellular contributions to
atherosclerosis have been controversial, the provisioning of cells
by EndMT was anticipated46–48 but difﬁcult to prove until the
present time18. Recently, a single publication emerged which
suggested that EndMT is modulated by FGF receptor 1 signalling,
and that this process is important during atherosclerosis18.
However, while an important contribution in its own right, that
study did not address the mesenchymal phenotype of the
EndMT-derived cells or quantitate the contribution of those
cells to atherosclerotic lesions, nor did it address the role of
oxidative stress and collagen-MMP balance.
Collectively, our in vitro and in vivo mouse data suggest that
EndMT-derived cells are present in intimal plaques throughout
atherosclerotic development and that this process is driven by
TGF-b signalling, oxidative stress and hypoxia. While it is well
known that apoptosis is abundant in atherosclerotic lesions49, it
was notable that a substantial proportion of intimal Yfpþ cells in
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advanced plaques appeared to be undergoing apoptosis (Fig. 3b).
Potentially, while increases in oxidative stress (Fig. 3a) and
hypoxia (Fig. 4a) with athero-progression may promote EndMT,
enhanced apoptosis may act as a compensatory mechanism to
maintain a relatively constant proportion of intimal EndMT-
derived cells in advanced lesions (Fig. 2).
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Figure 6 | EndMT leads to a ﬁbroblast-like phenotype with altered collagen-MMP balance. (a) Hierarchical cluster analysis based on global gene
expression demonstrating that untreated and TGF-b-only-treated HUVECs are intermixed and clustered together, while HUVECs treated with TGF-bþH2O2
cluster separately. Human ﬁbroblasts clustered separately again to all endothelial-derived cells (untreated, TGF-b-only- and TGF-bþH2O2-treated HUVECs).
x axis (1-correlation) indicates strength of correlation. Each data point (leaf of dendrogram) represents a separate sample for those conditions. (b) Principal
component analysis for HUVECs (untreated, TGF-b-only and TGF-bþH2O2 treated) and human ﬁbroblasts based on genes presented in Fig. 3d and
Supplementary Table 2. (c) Comparison of genes and transcription factors expressed by ﬁbroblasts and EndMT-derived ﬁbroblast-like cells (TGF-bþH2O2-
treated HUVECs). Expression levels of 5 of 19 mesenchymal/ﬁbroblast genes were statistically indistinguishable between these cell populations, while a single
gene (MYH9) was more highly expressed in EndMT-derived ﬁbroblast-like cells. (d) Comparison of expression of genes involved in extracellular matrix
organization between human ﬁbroblasts and EndMT-derived ﬁbroblast-like cells demonstrating differing balance between collagen and MMP transcript
production between these populations. (e) Global MMP protein activity assay, demonstrating 3-fold lower MMP activity in the cell lysates of EndMT-derived
ﬁbroblast-like cells but an 8.2-fold increase in MMP activity in the conditioned media from these cells, compared with human ﬁbroblasts; ****Po0.0001; n¼4
in all groups. (f) Conditioned media from EndMT-derived ﬁbroblast-like cells exhibited greater protein levels of MMP1, 9 and 10 and TIMP2 and 4,
compared with human ﬁbroblast conditioned media. Conversely, ﬁbroblast conditioned media had higher levels of MMP3. The levels of MMP2 and TIMP1
were not different between cell populations, while MMP8 and MMP13 were not present at detectable levels (not shown). **Po0.01, ***Po0.001,
****Po0.0001; n¼4 in all groups.
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The precise extent of EndMT varied somewhat depending on
the conditions and markers studied. In mice, among all intimal
cells, endothelial-derived Fapþ cells represented 3–9% cells
(Fig. 2g), whereas endothelial-derived Fsp-1þ cells represented
3.0–4.5% of cells and endothelial-derived Vimentinþ cells
represented 10–26% of cells (Supplementary Figs 5g and 6g,
respectively). On the other hand, in humans we found that 4–18%
of cells in intimal plaques co-expressed endothelial and ﬁbroblast
markers (Fig. 5), which was dependent on both the marker
combination used and lesion classiﬁcation (type V versus VI). As
important limitations, Vimentin may also mark activated
endothelial cells as well as ﬁbroblasts and transitioned ﬁbro-
blast-like cells50, while vWF may overestimate the proportion of
endothelial cells51. Furthermore, this variability we observed
almost certainly reﬂects the fact that there are various ﬁbroblast
sub-types (that are likely to be marked differently by our various
antibodies) and that there is no single ‘universal’ ﬁbroblast
marker. As a ﬁnal consideration, in contrast to humans, in mice
plaques typically do not rupture and the identiﬁcation of
vulnerable and unstable plaques is rarely performed because it
is arbitrary and of uncertain relevance. Therefore, while it appears
from our human data that unstable and ruptured plaques exhibit
more EndMT, this must be distinguished from our murine data,
where we found that plaques from mice with early versus
advanced atherosclerosis (8, 18 or 30 weeks of HFD) had a similar
extent of EndMT. Overall, taking these many factors into
account, we estimate that the true extent of endothelial-derived
ﬁbroblast-like cells in atherosclerotic intimal lesions is in the
order of 5–15%, which in humans is further inﬂuenced by the
morphological nature of the plaque itself (stable versus unstable,
ruptured versus non-ruptured and so on).
Our data inform our understanding of the context- and milieu-
speciﬁc nature of EndMT. In our in vitro models, we observed a
differing degree of cell transitioning and ﬁnal mesenchymal
phenotype depending on the speciﬁc EndMT-inducing condi-
tions (that is, TGF-b±H2O2±hypoxia) indicating that, while
different factors may trigger EndMT, the resulting mesenchymal
phenotype is variable and at least partially dependent on the
nature and strength of the inciting stimulus. Our in vivo data
similarly suggest that the mesenchymal cell phenotype that arises
via EndMT is milieu- and/or context-dependent, such that
VSMCs rarely arise from EndMT in plaques from ApoE /
mice, but that the differing milieu of a human plaque is conducive
to EndMT giving rise to both ﬁbroblast-like cells and a smaller
number of VSMCs. This is consistent with the broader
cardiovascular EndMT literature, with some investigators show-
ing that EndMT gives rise to ﬁbroblasts15, while in different
disease models we and others have identiﬁed that EndMT may
give rise to VSMCs9,17 or even other mesenchymal cell types such
as osteoprogenitor cells13,14. Furthermore, our ﬁnding that
EndMT gives rise to ﬁbroblast-like cells, but not to fully mature
ﬁbroblasts, is consistent with recent data indicating that renal
epithelial cells contribute to kidney ﬁbrosis by undergoing a
partial EMT to adopt a myoﬁbroblast-like phenotype52,53.
Further research will be required to fully unravel the molecular
cues that govern an EMT/EndMT event, which we speculate may
ultimately reveal that cell fate is determined by both cell extrinsic
factors (for example, milieu, stimulus) and cell intrinsic factors
(for example, epigenetic marks, cell metabolic status). Similarly, it
will be essential to explore and characterize the interaction of
these molecular cues with plaque development, and conversely
the impact of plaque progression and regression on the EndMT
process.
Atherosclerosis is one of the most common causes of morbidity
and mortality in the world54. Our data call for a revision of the
current model of the cellular basis of this disease, which previously
included only proliferating terminally differentiated local cells,
inﬁltrating inﬂammatory cells and a putative but poorly deﬁned
role for stem/progenitor cells. Our study has expanded this
framework and shown that phenotypic cell switching by EndMT is
a major additional feature of atherosclerosis (Fig. 7), with EndMT
potentially driving this disease by altering collagen-MMP balance.
The fact that in humans EndMT is more common in complex
lesions and ruptured plaques argues for the clinical importance of
this process.
Methods
Mice. Endothelial cell fate tracking experiments in atherosclerosis-prone mice were
performed using the tamoxifen-inducible end.SclCreERT;R26RstopYfp;ApoE /
murine line. With respect to the end.SclCreERT mouse line25, stem cell leukemia (Scl)
is a transcription factor expressed in endothelium and in subsets of hematopoietic cells
and the brain. Two distinct elements within the Scl locus guide expression to
endothelial cells. An Scl 50 endothelial enhancer directs expression to endothelium,
while a Scl 30 enhancer is responsible for Scl expression in early hematopoietic
progenitors and embryonic endothelium.25 In the end.SclCreERT mouse line the
creators used a 50 endothelial enhancer to achieve endothelial-speciﬁc expression of
the tamoxifen-inducible recombinase Cre-ERT25. The ﬁnal triple-crossed experimental
end.SclCreERT;R26RstopYfp;ApoE / mouse line was created by crossing ApoE /
mice with both end.SclCreERT and R26RstopYfp mice to create end.SclCreERT;
ApoE / and R26RstopYfp;ApoE / mice. These double-crossed lines were then
interbred to create end.SclCreERT;R26RstopYfp;ApoE / mice (Fig. 1). We also
created end.SclCreERT;R26RstopYfp mice during preliminary studies and as controls.
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Figure 7 | Schematic illustration of the cellular contributions to atherosclerotic plaques.
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Mice were sourced as follows: end.SclCreERT mice25 were obtained from the
laboratory of Dr Manfred Boehm with the permission of the Telethon Institute for
Child Health Research and the creators Dr Glenn Begley and Dr Joachim Goethert;
Tie2Cre (stock number 008863), R26RstopYfp (stock number 006148), ApoE /
(stock number 002052) and WT mice were obtained from the Jackson Laboratory
(Bar Harbor, ME). All mouse lines were on a C57BL/6 genetic background. Induction
of Cre in end.SclCreERT mice was achieved by intraperitoneal injection of 1mg
tamoxifen (T5648, Sigma, St Louis, MO) dissolved in sterile peanut oil once daily for 1
week in 4-week-old mice, followed by 1 week off, then a second course of injections
daily for 1 week. Control mice received peanut oil only over the same intraperitoneal
injection schedule. To induce atherosclerosis, 6-week-old end.SclCreERT;R26RstopYfp;
ApoE / mice were commenced on a HFD (#88137; Harlan Laboratories,
Indianapolis, IN). Genotyping was performed by PCR ampliﬁcation using allele-
speciﬁc primers (Supplementary Table 6). All procedures and animal care were
approved by our institutional animal use committee and conformed to the animal care
guidelines at the Icahn School of Medicine at Mount Sinai.
While because of its direct relevance to the extent of atherosclerosis we report
mice in terms of the period of HFD received (8, 18 or 30 weeks of HFD), because
HFD-feeding was always commenced at 6 weeks of age, these three groups of mice
were always 14, 24 and 36 weeks of age, respectively. In accord with US National
Institutes of Health guidelines, mice were evenly balanced between males and
females for every experiment55.
Mouse tissue ﬁxation and immunohistochemistry. The thoracic aorta was
harvested from mice following 8, 18 or 30 weeks of HFD (at 14, 24 or 36 weeks of
age). After humane euthanasia, the thorax was entered and the heart swiftly
exposed. A generous rent was created in the right atrium. The left ventricle was
punctured using a 20-gauge needle, and 20ml of 1 PBS at 4 C was infused at
B2.5mlmin 1. Tissues were then ﬁxed in situ by perfusing the heart with 20ml
of an ice-cold solution of 0.1% glutaraldehyde and 1.5% paraformaldehyde in PBS.
Harvested tissues were placed in 20% sucrose overnight at 4 C, and then
embedded in Tissue Tek OCT embedding medium (#62550-01; Electron
Microscopy Sciences, Hatﬁeld, PA). Tissue blocks were kept at  80 C and were
subsequently sectioned at 10-mm thickness on a Leica cryostat (CM3050S, Leica,
Allendale, NJ) and placed on glass slides56. To avoid inhomogeneity of the
experimental substrate, only the thoracic aorta was harvested and analysed
(including for FACS analysis—see below).
For immunostaining on frozen sections, thawed slides were washed in PBS and
blocked using 20% donkey serum and 5% BSA in PBS with 0.1% Triton-100.
Diluted primary antibodies were applied overnight at 4 C as follows: anti-CD31
(#550274; BD Biosciences, San Jose, CA, 1:100), anti-Ve-Cadherin (sc-6458; Santa
Cruz, Dallas, TX, 1:50), anti-Fap (ab53066; Abcam, Cambridge, MA, 1:100),
anti-Fsp-1 (ab27957; Abcam, 1:400), anti-aSma (ab5694; Abcam, 1:200),
anti-Sm22a (ab14106; Abcam, 1:200), Cy3-conjugated anti-aSma (C6198; Sigma,
1:400), anti-Smmhc (BT-562; Biomedical Technologies, Stoughton, MA, 1:200),
FITC-conjugated anti-Gfp/Yfp (ab6662; Abcam, 1:150), anti-Gfp/Yfp (ab13970;
Abcam, 1:500), anti-CD68 (MCA1957; Abd Serotec, Raleigh, NC, 1:200), anti-
CD45 (#550539, BD Biosciences, 1:200), anti-Tgf-b (ab66043; Abcam, 1:100),
anti-Vimentin (ab24525; Abcam, 1:100). After washing with PBS three times,
diluted secondary antibodies (donkey Alexa Fluor 488, 546, or 594 (Invitrogen,
Grand Island, NY, 1:750) or goat Alexa Fluor 488, 546, 633 (Invitrogen, 1:750))
were applied for 1 h at room temperature. Slides were mounted using DAPI-
containing media (Vector Laboratories, Burlingame, CA). Control slides were
routinely stained in parallel by substituting IgG, or the speciﬁc IgG isotype, from
the same species for the primary antibody at the same ﬁnal concentration. Slides
were imaged using a confocal microscope (SP5 DM; Leica, or, LSM 510 Meta;
Zeiss, Jena, Germany). Arterial elastic laminae in the medial aortic layer are visible
in green and occasionally in red due to auto-ﬂuorescence. For cell counting, images
were independently coded and then analysed by an experienced member of our
laboratory in a blinded manner. For quantitation of the extent of EndMT, staining
was performed at each time-point with at least four images evaluated from each of
at least three spatially separated thoracic aortic sections per mouse. Data were
averaged per animal then used for statistical analyses.
Detection of hypoxia in atherosclerotic plaques. Hypoxia was detected using
pimonidazole hydrochloride (Hypoxyprobe, Hypoxyprobe Inc., Burlington, MA).
Mice were injected intraperitoneally with 60mg kg 1 body weight of the
pimonidazole agent. One hour later, mice were killed and perfused with 20ml of
1 PBS at 4 C as described above. Aortas were then harvested and mounted as
described above. After thawing, 10-mm sections were ﬁxed in cold acetone for
10min, washed and incubated overnight at 4 C with rabbit anti-pimonidazole
antisera diluted 1:20 in PBS containing 3% BSA. After further washing, sections
were labelled with DAPI and imaged by confocal microscopy as described.
Detection of oxidative stress and apoptosis in murine atherosclerotic plaques.
Oxidative stress in murine atherosclerotic plaques was determined by assessing
vascular superoxide production in situ using dihydroethidium (DHE) ﬂuorescence
microscopy. DHE is blue ﬂuorescent (absorption/emission: 355/420 nm) in cell
cytoplasm while the oxidized form ethidium is red ﬂuorescent (absorption/
emission: 518/605 nm) on DNA intercalation. Aortas were harvested without
ﬁxation, and then mounted and sectioned as described above. Next, 10 mmol l 1
DHE (D23107; Invitrogen), was applied to each tissue section and sections were
incubated in a dark humidiﬁed chamber at 37 C for 30min. Due to the staining
protocols, speciﬁc staining could only be performed using DHE (seen in red) and
DAPI (blue). Sections were imaged using a confocal microscope (SP5 DM; Leica).
For detection of apoptosis, mouse thoracic aortas underwent perfusion-ﬁxation
as described above and apoptotic cells were detected by immunoﬂuorescence using
an In Situ Cell Death Detection Kit (TUNEL assay; #12156792910910, Roche,
Indianapolis, IN). Slides were scanned using a confocal microscope (LSM 510
Meta; Zeiss).
Flow cytometry and sorting. For FACS-based characterization of circulating cells,
peripheral blood was obtained from end.SclCreERT;R26RstopYfp,
end.SclCreERT;R26RstopYfp;ApoE / and Tie2Cre;R26RstopYfp mice. Erythrocyte
lysis was performed using ACK lysing buffer (Invitrogen). Cells were then washed
with RPMI 1640 media (Fischer Scientiﬁc, Pittsburgh, PA) containing 0.1% BSA
and stained with CD45-APC (#559864; BD Biosciences, 1:100) or isotype control
(#553991; BD Biosciences, 1:100) as indicated. After washing with 0.1% BSA in
RPMI 1640 media, cells were analysed using a FACS LSRII ﬂow cytometer (BD
Biosciences).
For FACS of mouse aortic cells, preparations of digested thoracic aortic tissue
were obtained from end.SclCreERT;R26RstopYfp;ApoE / mice and
end.SclCreERT;R26RstopYfp mice as indicated. Aortas were digested with
2mgml 1 collagenase (C5138; Sigma) and 0.4mgml 1 elastase (E7885; Sigma) in
RPMI 1640 media at 37 C for 1 h. The digestion reaction was stopped by adding
20% fetal bovine serum (FBS) by volume of digestion solution. Cells were then
ﬁltered and washed with PBS containing 10% FBS. From this point forward, due to
the tendency of the Yfp protein to dissipate after ﬁxation and permeabilization,
differing protocols were used to detect cell surface versus intracellular proteins in
conjunction with Yfp. For FACS of Yfp with Fap, after resuspending cells in PBS
with 10% FBS, 7-AAD (Beckman Coulter, Brea, CA) was added and live, viable
cells were sorted into Yfp positive and Yfp negative populations using a BD
InﬂuxTM cell sorter (BD Biosciences). Following sorting, cells were ﬁxed in
ice-cold 4% paraformaldehyde for 10min, washed with PBS and blocked with
Mouse BD Fc BlockTM (#553141; BD Biosciences) for 15min. Cells were then
stained with anti-Fap-Alexa Fluor 647 (bs-5760R-A647; Bioss, Woburn, MA) in
PBS containing 0.5% Saponin for 2 h on ice. Cells were washed with PBS before
ﬂow cytometric analysis was performed on a BD LSR II Flow Cytometer. For FACS
of Yfp with cell surface-expressed CD31, live cells were incubated for 30min on ice
with Hoechst 33342 (H21492; Invitrogen) and anti-CD31-PECy7 (#25-0311-82;
eBiosciences). After washing, 7-AAD (Beckman Coulter, Brea, CA) was added, and
live, viable cells positive for Yfp and CD31 were quantiﬁed using a BD InﬂuxTM
cell sorter (BD Biosciences).
Human tissue immunostaining. Human abdominal aortic atherosclerotic
immunostaining was performed using pre-existing tissue blocks originally made
from autopsy samples as previously described and used in other studies57 and with
the approval of the Institutional Review Board of the Icahn School of Medicine at
Mount Sinai (determined to be ‘not human subjects research’ due to strict sample
de-identiﬁcation). Plaques were classiﬁed into AHA type V or VI lesions according
to standard criteria using H&E staining (other plaque types were excluded)40.
Fibrous cap thickness was measured using a pre-calibrated ocular micrometer
during microscopy. For immunoﬂuorescence staining on formalin-ﬁxed, parafﬁn-
embedded human samples, slides were deparafﬁnized by twice washing for 5min
in Xylene, followed by two washes in 100% ethanol for 2min each, and a series of
sequential 2min washes each in 90, 80, 70 and 50% ethanol, followed by rinsing in
PBS. Proteinase K (S3004; Dako, Denmark) was used according to manufacturer’s
instructions. Antigen retrieval was performed in a solution of 10mM sodium
citrate, pH 6.0 for 40min at 95 C. After cooling, samples were blocked for 1 h in
5% BSA and 20% donkey serum in PBS, then primary antibodies were applied
overnight at 4 C in 3% BSA as follows: anti-CD31 (ab9498; Abcam, 1:50), anti-
CD31 (M0823; Dako, 1:100), anti-FAP (ab28244; Abcam, 1:100), anti-FSP-1
(ab27957; Abcam, 1:100), anti-vWF (A0082; Dako, 1:200), anti-vWF (ab68545;
Abcam, 1:100), anti-aSMA (ab5694; Abcam, 1:100), FITC conjugated anti-aSMA
(F3777; Sigma, 1:200), anti-SM22a (ab14106; Abcam, 1:100). Slides were then
washed and the secondary antibody applied as indicated for 1 h at room
temperature (anti-mouse or anti-rabbit conjugated to Alexa Fluor 594 or
anti-rabbit conjugated to Alexa Fluor 488, Invitrogen, 1:750). Slides were imaged
using a confocal microscope (SP5 DM; Leica). To permit more detailed analyses
including linear regression and increase statistical power, we evaluated more
samples with the marker combination of vWF with FAP (see Figure legends for
sample numbers). For cell counting, images were coded and analysed by an
experienced member of our laboratory in a blinded manner.
Cell culture and induction of EndMT. HUVECs (Lonza, Basel, Switzerland) and
HCAECs (Lonza) were cultured in EGM-2 media (Lonza). To induce EndMT,
six-well plates were pre-coated with 31.25 ngml 1 ﬁbronectin (F2006; Sigma) for
1 h. HUVECs or HCAECs were initially seeded at 5,000 or 7,500 cells cm 2,
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respectively. Growth medium was changed for complete growth medium
containing 50 ngml 1 TGF-b2 (#100-35; Peprotech, Rocky Hill, NJ) with or
without hydrogen peroxide (H2O2) (H1009; Sigma) at 100 or 200mM (as indi-
cated)58 the following morning and every other day for 5 days.
Endothelial cell culture under hypoxic conditions was performed by incubating
the cells in an airtight Plexiglass chamber (Billups-Rothenberg Modular Chamber;
Del Mar, CA) with an atmosphere of 5% CO2/95% N2 at 37 C, as described59.
Rather than changing growth media every other day, to minimize cell exposure to
oxygen the media was replaced only once during the 5-day experiment. Media was
also changed only once during the 5-day experiment for control (comparator) cells
grown under non-hypoxic conditions.
Quantitative real-time PCR. RNA was isolated from human cultured cells using
Trizol-based methods (Invitrogen). In brief, 1ml of Trizol was added to each well
of a six-well plate. RNA was extracted by phase separation in chloroform. RNA was
precipitated by mixing with isopropyl alcohol, and was puriﬁed by incremental
ethanol washes. RNA was diluted in RNase- and DNase-free water and stored at
 80 C until use. RNA was quantiﬁed using a Nanodrop NP-1000 spectrometer
(Wilmington, DE). Reverse transcription was performed using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Reaction conditions were: 25 C for 5min,
42 C for 30min, 85 C for 5min and 4 C forever. Subsequently, qRT-PCR was
performed using the PerfeCTa SYBR Green FastMix Reaction Mixes kit (vWR,
Radnor, PA) according to manufacturer’s protocol. 18S rRNA served as control.
Conditions for qRT-PCR were as follows: 95 C for 5min, with 40 cycles consisting
of 95 C for 15 s and 60 C for 1min; 95 C for 15 s and 60 C for 15 s. RNA
expression was analysed using the DCt method. Primer sequences are provided in
Supplementary Table 6.
Immunoblotting. HCAECs and HUVECs were lysed using Laemmli Sample
Buffer (Bio-Rad) mixed with b-mercaptoethanol. After sonication and heating,
samples were analysed by western blot (4–20% Novex Tris-Glycine Gel, Invitro-
gen). Primary antibodies used were as follows: anti-FAP (ab53066, Abcam; 1:500),
anti-CD31 (ab9498, Abcam; 1:1,000), anti-active Caspase 3 (ab13847; Abcam,
1:1,000), anti-SM22a (ab14106, Abcam; 1:1,000), anti-phospho-SMAD3 (ab51451,
Abcam; 1:1,000), anti-SMAD3 (#9513, Cell Signaling, Danvers, MA; 1:1,000) and
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (G8795, Sigma;
1:10,000). Original uncropped immunoblots from all Figures in this manuscript
(Figs 3e,g and 4m,n; Supplementary Figs 9c and 10g) are presented as
Supplementary Figs 16–21.
Immunocytochemistry. Immunostaining of HCAECs and HUVECs was
performed under control conditions and following TGF-b2±H2O2±hypoxia
treatment. After ﬁxing with 4% paraformaldehyde for 10min and washing with
PBS, blocking solution (5% normal donkey serum in PBS with 0.1% Triton-X100)
was applied for 1 h. The following primary antibodies were applied overnight at
4 C: anti-active Caspase 3 (ab13847; Abcam, 1:100), anti-SM22a (ab14106;
Abcam; 1:100), anti-FAP (ab53066; Abcam; 1:100), anti-CD31 (ab9498; Abcam;
1:50), anti-Ve-Cadherin (sc-6458; Santa Cruz, 1:50). Cells were washed with PBS,
and corresponding secondary antibodies were applied for 1 h at room temperature.
Nuclear staining was performed through immersion in DAPI (Invitrogen #D3571;
1:1,000). Apoptosis staining of HUVECs was detected using ApopTag In Situ
Apoptosis Detection Kit (S7100; Millipore, Billerica, MA) according to the
manufacturer’s instructions.
For staining of human ﬁbroblasts, cultured cells were ﬁxed in methanol at
 20 C for 10min, washed, and permeabilized in PBS with 0.1% Tween 20 for
10min at room temperature. After blocking, the following primary antibodies were
applied overnight at 4 C: anti-FAP (ab53066; Abcam; 1:100), anti-Vimentin
(ab20346; Abcam, 1:100), anti-FSP-1 (ab27957; Abcam, 1:100). Cells were washed
with PBS, and corresponding secondary antibodies were applied for 1 h at room
temperature.
Nuclear staining was performed through immersion in DAPI (Invitrogen
#D3571; 1:1,000). A minimum of three replicates was performed for every
observation.
In vitro cell viability and counting. We initially assessed the number of apoptotic
and dead HUVECs using FITC Annexin V Apoptosis Detection kit (BD
Pharmingen) according to the manufacturer’s instructions. Brieﬂy, HUVEC treated
with TGF-b2±H2O2 for 48 h (consistent with the proliferation assay) were gently
trypsinized, washed with cold PBS and resuspended in binding buffer. We then
stained 106 cellsml 1 with FITC Annexin V and propidium iodide (PI) at room
temperature for 15min. The number of apoptotic and dead cells was estimated by
ﬂow cytometry using a FACS LSRII ﬂow cytometer equipped with Diva software
(BD Biosciences). However, because this assay required trypsinization, we were
concerned this may cause apoptotic cells to die with a consequent mis-
representation of cell apoptosis. Therefore only cell death was quantitated by this
method. Apoptosis was assessed by western blot and immunostaining for
apoptosis-associated proteins and TUNEL assay (ApopTag In Situ Apoptosis
Detection Kit—see above). Cell counting was performed after 5 days of treatment
with TGF-b2±H2O2 following gentle trypsinization and using a hemocytometer.
Proliferation assay. Proliferation was measured using a Cell Proliferation ELISA,
BrdU (colorimetric) assay kit (Roche) according to the manufacturer’s instructions.
Brieﬂy, HUVECs were seeded in a 96-well plate. The following morning, media was
changed for complete growth medium containing 50 ngml TGF-b2±H2O2. Eight
hours later, BrdU was added to each well for a further 16 h. Cells were then ﬁxed
and anti-BrdU-POD was added to each well to detect the immune complex by
substrate reaction. The reaction product was quantiﬁed by measuring absorbance
at 370 nm using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA). Three wells
per experiment were analysed, and three experiments were performed.
Migration and invasion assays. Cell migration was assessed using a 24-well QCM
Chemotaxis cell migration assay (Millipore) with 8 mm pore size, as per the
manufacturer’s instructions. HUVECs were cultured in basal media or with
50 ngml 1 TGF-b2 (#100-35; Peprotech) and 200mM H2O2 as described for 5
days. Cells were resuspended in EBM-2 serum-free medium, counted and plated
onto the chemotaxis insert at 37,500 cells per chamber in triplicate. Cells were
allowed to migrate overnight towards EBM-2 mediaþ 10% FBS at 37 C. Cells were
stained for 20min at room temperature, washed in distilled water and non-
migrated cells remaining on the upper chamber of the insert were scraped off using
a cotton swab. Migrated cells were then dissolved in extraction buffer. Cell solution
was transferred to a 96-well plate and the optical density was read at 560 nm.
Absorbance values were normalized to the average of the unstimulated samples.
Migration was calculated from three independent experiments.
Cell invasion was assessed using 24-well, 8 mM polycarbonate Transwell inserts
(Corning Costar Inc., Tewksbury, MA). Inserts were coated with growth factor-
reduced Matrigel at a concentration of 1mgml 1 for 1 h at room temperature.
After induction of EndMT for 5 days with TGF-b and 200 mM H2O2 as described,
unstimulated and treated cells were resuspended in EBM-2 serum-free medium,
counted and plated onto inserts at 15,000 cells per insert in duplicate. After 24 h,
invading cells were washed in PBS and ﬁxed in ice-cold 70% ethanol for 10min.
Non-invaded cells were scraped from the upper chamber of the insert with a cotton
swab and inserts were washed again in PBS. Membranes were removed from the
insert with a scalpel blade and mounted onto a glass slide using Vectashield
containing DAPI (Vector Laboratories). Cells were imaged in ﬁve random ﬁelds
per membrane at  10 magniﬁcation and counted using ImageJ software (National
Institutes of Health, Bethesda, MD). Cell invasion was calculated from three
independent experiments.
MMP activity and protein assays. After standard induction of EndMT with
TGF-b and 200 mM H2O2 in HUVECs or culture of human ﬁbroblasts as described
above and then careful washing, EBM-2þ 0.2% FBS was applied to the cells for
16 h. Conditioned media was collected and cells were lysed in RIPA buffer and
samples stored at  80 C pending analysis. MMP activity was measured using a
SensoLyte 520 Generic MMP Fluorimetric Assay Kit (AS-71158; Anaspec, Fre-
mont, CA) according to the manufacturer’s instructions. Conditioned media was
applied undiluted and cell lysates were diluted in assay buffer to a concentration of
200 ngml 1. EBM-2þ 0.2% FBS was used as negative control. The ﬁnal reaction
was measured using a SpectraMax M5 with an excitation of 490 nm and emission
detected at 520 nm (Molecular Devices, Sunnyvale, CA).
Speciﬁc MMP and TIMP protein levels were measured using the Quantibody
Human MMP Array 1 (QAH-MMP-1; RayBiotech, Norcross, GA) for the
detection of MMP1, 2, 3, 8, 9, 10, 13 and TIMP1, 2 and 4. Undiluted conditioned
media was applied to the array as per the manufacturer’s instruction, and
EBM-2þ 0.2% FBS used as a negative control. The array was scanned using an
Axon GenePix laser scanner (Molecular Devices) with a Cy3 wavelength.
Densitometry data was acquired using ImageJ software. All samples were
normalized to an internal positive control, and MMP/TIMP protein quantiﬁcation
obtained using standards of known concentration.
Microarray sample preparation. Primary human ﬁbroblasts were obtained from
skin biopsy samples from three healthy control subjects enrolled in the CAUSE
study (ClinicalTrials.Gov Identiﬁer: NCT01808729). This study was approved by
the Institutional Review Board of the Icahn School of Medicine at Mount Sinai, and
all subjects provided written informed consent. Freshly obtained skin biopsy
samples were washed, disrupted, plated in DMEM/F-12 media (#11330-032; Gibco,
Grand Island, NY) with 20% FBS and incubated at 37 C under a cover slip. After
B4 weeks, ﬁbroblasts were detached and passaged. All ﬁbroblast lines were then
uniformly passaged and used for ﬁnal experiments atoP7. Prior to harvesting for
RNA extraction, ﬁbroblasts were switched to DMEM/F-12 media with 5% FBS for
24 h to replicate HUVEC culture conditions (EGM-2 media contains 5% FBS).
HUVECs were grown as described. RNA was isolated from both HUVECs and
ﬁbroblasts using the RNeasy mini Kit (Qiagen, Germantown, MD) according to the
manufacturer’s instructions. Residual DNA was removed using the RNase-Free
DNase Set (Qiagen) on-column DNase treatment during RNeasy preparation. RNA
was ampliﬁed by Illumina TotalPrep RNA Ampliﬁcation Kit and hybridized to the
HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA). This chip was
scanned using an Illumina HiScan.
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Statistical and bioinformatics analyses. For cell culture, each individual experi-
ment was repeated at least three times. Where appropriate, mice were randomized
into experimental groups by random number generator. Statistical power was
determined from prior studies from our laboratories using similar models17,56. Data
were normalized, as appropriate, to means of each experiment with the reference
condition set at 1. Experimental data were analysed by unpaired two-tailed t-test,
one-way analysis of variance with post hoc Dunnett’s (with baseline as the reference)
or Newman–Keuls (if multiple inter-group comparisons were appropriate) multiple
comparison tests, or two-way analysis of variance with Bonferroni posttests as
indicated. Results are expressed as mean±s.e.m. Linear regression was used to model
the relationship between ﬁbrous plaque cap thickness and % FAPþvWFþ
co-positive cells in human atherosclerotic plaques. Differences were deemed
signiﬁcant when Po0.05. These analyses were performed using Prism, Version 4.00
(GraphPad Software) or STAT VIEW software package (SAS, Cary, NC).
For microarray data analysis, images generated by the Illumina Hiscan were
uploaded into GenomeStudio Software for primary data extraction and analysis.
Spurious probes were ﬁltered by translating the detection P values into q values60,61
and removing any probe with maximum q value across all samples Z10%.
Differential expression analysis of the resulting log2-transformed data was
performed with signiﬁcance analysis of microarrays using its default
parameters33,34, and genes assigned a false discovery rate o5% were considered
differentially expressed. Enriched pathways and other gene sets, such as
extracellular matrix organization genes, were identiﬁed in the resultant lists of
differentially expressed genes using the ingenuity pathway analysis (Ingenuity
Systems, Redwood City, CA) and molecular signature database62 applications,
respectively (with a false discovery rateo5% indicating enrichment). Clustering of
gene expression data was performed using the group-average hierarchical
clustering algorithm with Pearson’s correlation as the similarity metric. This
computation and visualization of the resultant dendrogram was done using Matlab
(Mathworks, Natick, MA), along with additional veriﬁcation of the robustness of
these results using single-linkage algorithm, Euclidean distance and other options
for hierarchical clustering. Principal component analysis on the expression proﬁles
across all cell types of the EndMT-related genes (Supplementary Table 2) was also
performed and the results visualized in Matlab. Microarray data are deposited in
GEO, accession number: GSE56309.
Data availability. Microarray data that support the ﬁndings of this study have
been deposited in NCBI’s Gene Expression Omnibus (GEO), and are accessible
through GEO series accession number GSE56309. Original blots used for protein
quantiﬁcation supporting the ﬁndings of this study are available within the article
(and its Supplementary Information Files). Other data that support the ﬁndings of
this study are available from the corresponding author upon request.
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